Catalog No.
Product Name
Application
Product Information
Citations
-
IL-2 secretion inhibitor
BC12-4 is a potent inhibitor of interleukin-2 (IL-2) secretion, primarily acting on immune cell signaling pathways. This compound exhibits immunomodulatory activity, making it valuable in the study of cytokine regulation and immune responses. BC12-4 is suitable for research applications focused on autoimmune diseases, transplantation, and cancer immunotherapy. -
IL-1/β-transferase Inhibitor
Pentenocin A is an inhibitor of IL-1β-transferase, also known as interleukin-1 converting enzyme (ICE). This compound displays weak inhibitory activity against the processing of pro-inflammatory cytokine IL-1β, making it useful for studies related to inflammation and immune response. Its applications can extend to research exploring pathways involved in cytokine maturation and signaling, contributing to the understanding of various inflammatory diseases. -
IL-2 Inhibitor
Digitoxigenin-3-O-β-D-quinovoside is a potent interleukin-2 (IL-2) inhibitor, exhibiting an IC50 value of 52 nM. This cardiac glycoside is derived from the plant Elaeodendron australe var. integrifolium. It is useful in research applications focused on immune modulation and the investigation of IL-2 signaling pathways, providing valuable insights into related therapeutic areas. -
IL-1β Inhibitor
Shegansu B is a potent inhibitor of IL-1β, demonstrating significant inhibition of IL-1β expression in LPS-induced THP-1 cells, achieving an inhibition rate of 64.74%. This compound exhibits noteworthy anti-inflammatory activity, making it a valuable tool for research applications focused on inflammation and immune response modulation. Its selective targeting of IL-1β positions Shegansu B as an important reagent for studies aimed at understanding inflammatory processes and potential therapeutic interventions. -
IL-1β Processing Inhibitor
CP-424174 is a reversible inhibitor of IL-1β processing, acting with an IC50 of 210 nM. By indirectly inhibiting the NLRP3 inflammasome, CP-424174 plays a critical role in modulating inflammatory responses. This compound is useful for research applications focused on understanding the mechanisms of inflammation and potential therapeutic interventions in inflammatory diseases. -
Anti-PD-1 Antibody/IL-21 Mutein
Latikafusp is a bifunctional fusion protein that functions as an anti-PD-1 antibody paired with an IL-21 mutein. This compound is designed to stimulate the IL-21 pathway specifically in PD-1+ cells, enhancing the priming and persistence of cytotoxic and memory T cells to promote anti-tumor immunity. Latikafusp is particularly relevant in research focused on solid tumors and has the potential to elicit immunogenicity-mediated responses. -
IL-17A Inhibitor
LY3509754 is a potent IL-17A inhibitor, demonstrating IC50 values of less than 9.45 nM in alphaLISA assays and 9.3 nM in HT-29 cell assays. This compound's selective inhibition of IL-17A makes it a valuable tool for investigating the role of IL-17A in inflammatory diseases and immune responses. Its use in research applications can help elucidate the therapeutic potential for conditions associated with IL-17A signaling. -
IL-17A antagonist
IL-17A antagonist 1 is a potent inhibitor of the interleukin-17A cytokine, demonstrating a binding affinity (Kd) of 0.66 μM and an inhibitory concentration (IC50) of 1.14 μM. This compound effectively modulates IL-17A signaling, making it a valuable tool for studying inflammatory responses and autoimmune disorders. It is suitable for research applications focused on understanding the role of IL-17A in various biological processes and therapeutic interventions. -
IL-15 Agonist
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain fused with human IgG1 Fc, serving as an IL-15 superagonist. This compound forms a complex with the IL-15 antibody Nogapendekin alfa, enhancing anti-CD20 monoclonal antibody-mediated natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC). Inbakicept significantly promotes degranulation and interferon-gamma (IFNγ) production in NK cells, making it a valuable tool for research in immunotherapy and cancer treatment strategies. -
IL-17 Modulator
IL-17 Modulator 4 is a proagent of IL-17 Modulator 1, serving as an IL-17 inhibitor targeting the interleukin-17 pathway. This compound exhibits potent modulation of IL-17A and is significant for research into IL-17A mediated diseases, including various inflammatory and autoimmune conditions, as well as infectious diseases and cancer. Its application in preclinical studies may enhance understanding of the therapeutic potential in these pathologies. -
IL-2R Agonist
Nemvaleukin alfa is an IL-2 fusion protein that selectively targets intermediate-affinity IL-2 receptors (IL-2R). Its mechanism involves activating natural killer (NK) cells and effector T cells, thereby enhancing immune responses. This reagent is utilized in cancer research to investigate immune modulation and therapeutic strategies aimed at improving anti-tumor immunity. -
IL-22 Activator
Efmarodocokin alfa is a fusion protein comprising human IL-22 and the IgG4 crystallizable fragment, functioning primarily as an IL-22 activator. This reagent enhances IL-22 signaling pathways, contributing to the modulation of immune responses. It is particularly relevant for research applications focused on severe COVID-19 pneumonia, facilitating studies on therapeutic strategies that leverage IL-22 in inflammation and tissue repair processes. -
IL-17 Modulator
IL-17 modulator 3 is a specific IL-17 modulator that targets the IL-17 signaling pathway, playing an essential role in immune regulation. It exhibits potential anti-inflammatory properties and is valuable for research into inflammatory conditions, cancer, and autoimmune diseases. This compound offers insights into the modulation of IL-17 related pathways in various biological contexts. -
IL6/STAT3 Inhibitor
Angoline is a selective inhibitor of the IL6/STAT3 signaling pathway, demonstrating an IC50 of 11.56 μM. It effectively inhibits the phosphorylation of STAT3, leading to reduced expression of target genes associated with cancer progression. This compound is valuable for research applications focused on cancer biology and the modulation of inflammatory responses. -
IL-17A Antagonist
Simepdekinra is an IL-17A antagonist that plays a crucial role in modulating inflammatory responses. It demonstrates significant potential in the research of moderate to severe plaque-type psoriasis by inhibiting the activity of IL-17A, a key cytokine involved in the pathogenesis of this condition. Its application in preclinical studies provides valuable insights into therapeutic strategies targeting autoimmune skin diseases. -
IL-2/IL-2Rα Inhibitor
SP4206 is an inhibitor of the IL-2/IL-2Rα interaction, exhibiting high-affinity binding to IL-2 with a dissociation constant (Kd) of 70 nM. By effectively blocking the interaction with its natural receptor IL-2Rα, which has a Kd of 10 nM, SP4206 has significant potential for modulating immune responses. This compound is valuable for research applications focused on autoimmune diseases, cancer immunotherapy, and enhancing our understanding of IL-2-mediated signaling pathways. -
IL-18 Inhibitor
NSC80734 is an IL-18 inhibitor that effectively disrupts the binding of human IL-18 to ectromelia virus IL-18 binding protein (IL-18BP). This compound inhibits the IL-18-mediated production of interferon-gamma (IFN-γ), making it a valuable tool for studying the role of IL-18 in inflammatory processes and immune responses. NSC80734 is applicable in research focusing on cytokine signaling and related biological pathways. -
IL-17C/IL-17RE Interaction Inhibitor
Lib2-1 is a macrocyclic peptide that functions as an inhibitor of the IL-17C/IL-17RE interaction. This compound demonstrates significant potential in modulating inflammatory responses, making it a valuable tool in the study of autoimmune and inflammatory diseases. Researchers can utilize Lib2-1 to investigate the underlying mechanisms of IL-17C signaling and its implications in various pathological conditions. -
IL-15 Agonist
Nogapendekin alfa (his tag) is a soluble protein subunit of a human interleukin-15 variant, acting as a potent superagonist of IL-15. It enhances the proliferation and survival of immune cells, making it valuable for various immuno-oncology studies. In combination with Inbakicept, Nogapendekin alfa forms the IL-15 cytokine-antibody fusion protein N-803, which has demonstrated the ability to reduce tumor burden through the activation of natural killer (NK) cells and CD8+ T cells. This reagent is instrumental in research applications targeting cancer immunotherapy and immune response modulation. -
IL-17A Antagonist
IL-17A antagonist 3 is a selective inhibitor of IL-17A, a pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. This compound effectively blocks the interaction of IL-17A with its receptor, leading to reduced downstream inflammatory responses. It is applicable in research focused on the pathophysiology of conditions such as psoriasis, rheumatoid arthritis, and other IL-17-mediated disorders. -
IL-17A Modulator
IL-17A modulator-2 selectively targets interleukin-17A (IL-17A), functioning as a potent inhibitor with a pIC50 of 8.3. This compound effectively modulates the biological activity of IL-17A, making it valuable for research into a variety of conditions linked with IL-17A dysregulation. Applications include investigations into autoimmune diseases, cancers, and neurodegenerative disorders where IL-17A plays a significant role in pathogenesis. -
IL-18 Inhibitor
NSC61610 is an inhibitor of interleukin-18 (IL-18) that disrupts the binding of human IL-18 to the ectromelia virus IL-18 binding protein (IL-18BP). It effectively inhibits the formation of the hIL-18:ectvIL-18BP complex, demonstrating an IC50 of approximately 6 µM. This compound is valuable for research applications involving inflammatory responses and the study of viral interactions with host immune mechanisms. -
IL-17A Modulator
IL-17A modulator-1 is a selective modulator of interleukin-17A (IL-17A) that inhibits its biological activity with a pIC50 of 8.2. This compound is valuable for research into diseases associated with dysregulation of IL-17A, including autoimmune disorders, cancers, and neurodegenerative diseases. Its ability to modulate IL-17A activity makes it a pertinent tool for studies investigating immune responses and therapeutic interventions. -
IL-1 Inhibitor
Lys-D-Pro-Thr is an IL-1β analogue, specifically targeting the positions 193-195 of the IL-1β protein. It acts as a potent inhibitor of IL-1, playing a critical role in regulating inflammatory responses. This reagent is valuable for research applications focused on inflammatory pathways, autoimmune diseases, and the modulation of cytokine signaling. -
IL-17A Inhibitor
Navepdekinra is a potent inhibitor of interleukin-17A (IL-17A), with an IC50 of 10.81 nM. By disrupting the interaction between IL-17A and its receptor, Navepdekinra effectively suppresses downstream pro-inflammatory signaling pathways. This compound has demonstrated efficacy in reducing arthritis symptoms in a collagen-induced arthritis rat model and is applicable to research in psoriasis, psoriatic arthritis, and ankylosing spondylitis. -
FAPα/IL-2Rβγ Immunocytokine
Simlukafusp alfa is an immunocytokine composed of an antibody targeting fibroblast activation protein α (FAPα) and a variant of interleukin-2 (IL-2) that selectively engages the IL-2 receptor βγ chain. This unique structure enhances the immune response against FAPα-expressing tumors while promoting T-cell activation and proliferation. Simlukafusp alfa is suitable for research applications focused on cancer immunotherapy and the study of tumor microenvironments, particularly in evaluating the efficacy of targeted immune modulation. -
IL-1 Antagonist
Goflikicept is an IL-1 antagonist that functions as a fusion protein, selectively binding to and neutralizing both IL-1β and IL-1α. This mechanism of action positions Goflikicept as a valuable tool for research focused on inflammatory conditions, particularly in the context of ST-segment elevation myocardial infarction (STEMI). Its ability to modulate IL-1 signaling pathways makes it relevant for studying various cardiovascular and autoimmune disorders. -
IL-23R Inhibitor
IL-23R inhibitor peptide-1 is a potent interleukin-23 receptor inhibitor with an IC50 of 0.0069 μM. It is designed to modulate the signaling pathway of IL-23, which plays a critical role in the pathogenesis of various autoimmune diseases. This reagent is suitable for research applications focused on inflammatory responses and therapeutic strategies targeting IL-23 signaling. -
IL-17 Modulator
(R)-IL-17 modulator 4 is a selective modulator of IL-17, functioning as a proagent for IL-17 modulator 1, a potent and orally active IL-17 inhibitor. This compound exhibits significant biological activity in the modulation of IL-17A signaling pathways, making it valuable in the study of IL-17A mediated diseases. Research applications include investigating its role in inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes. -
IL-2 Inhibitor
IL-2-IN-1 is a potent inhibitor of interleukin-2 (IL-2), exhibiting an IC50 value of 1978 nM. It demonstrates significant antiproliferative activity, making it a valuable tool for research in immune modulation and cytokine signaling. This compound is ideal for studies focused on T cell regulation and potential therapeutic applications in autoimmune diseases and cancers linked to IL-2 signaling. -
IL-20/PRINS Inhibitor
Abacavir hydroxyacetate is an orally active inhibitor of IL-20 and PRINS. This compound demonstrates significant immune modulation, effectively reducing the proliferation rate of skin cells in psoriasis. It serves as a valuable tool for investigating inflammatory skin disorders and potential therapeutic strategies in related research applications. -
IL-1β Inhibitor
IL-1β-IN-2 is a potent inhibitor of interleukin-1 beta (IL-1β), a key mediator in inflammatory processes. This cannabigerol derivative exhibits significant anti-inflammatory and analgesic effects, making it a valuable tool for research into conditions driven by IL-1β signaling. IL-1β-IN-2 is suitable for studies focused on inflammatory diseases and pain management, aiding in the understanding and development of therapeutic strategies targeting IL-1β. -
IL-17 Modulator
IL-17 Modulator 1 disodium is a potent inhibitor targeting the IL-17 signaling pathway. This compound demonstrates significant biological activity in mitigating inflammatory responses, making it valuable for research applications related to autoimmune conditions such as psoriasis, ankylosing spondylitis, and psoriatic arthritis. Its oral bioavailability further enhances its utility in preclinical studies aimed at understanding and developing therapies for IL-17 associated diseases. -
IL-1β Inhibitor
IL-1β-IN-1 is a selective inhibitor of interleukin-1 beta (IL-1β), a key cytokine involved in inflammatory processes. This compound demonstrates significant anti-inflammatory and analgesic effects, making it a valuable tool in research focused on chronic inflammatory conditions and pain management. Its potency and specificity for IL-1β allow for detailed studies on its biological roles and therapeutic applications. -
IL-17 Inhibitor
IL-17-IN-2 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.4 μM, as demonstrated in both HTRF and NHK assays. This compound effectively disrupts IL-17 signaling, making it valuable for research related to inflammatory diseases and immune response modulation. Its significant biological activity allows for exploration in therapeutic contexts targeting IL-17-mediated pathways. -
Anti-IL-17C Antibody
MOR-106 is a humanized anti-IL-17C IgG1 monoclonal antibody that targets interleukin-17C, a cytokine involved in inflammatory responses. By binding specifically to IL-17C, MOR-106 inhibits the NF-κB signaling pathway, demonstrating an IC50 of 59 pM for human IL-17C and 55 pM for mouse IL-17C. This reagent effectively reduces skin inflammation and associated inflammatory factors in preclinical models of psoriasis and atopic dermatitis, making it a valuable tool for research into inflammatory skin disorders. -
IL-17 Modulator
IL-17 Modulator 4 Sulfate targets the IL-17 signaling pathway, functioning as a proagent of IL-17 Modulator 1. This compound exhibits potent modulatory effects on IL-17A, making it a valuable tool for investigating IL-17A mediated diseases. Its applications extend across various fields, including inflammation, autoimmune disorders, infectious diseases, cancer, and precancerous syndromes, facilitating a deeper understanding of these conditions. -
Anti-IL-15RA Antibody
Larnefpendekin alfa is an anti-IL-15RA antibody designed to target and inhibit the interleukin-15 receptor alpha (IL-15RA). This fusion protein plays a pivotal role in modulating immune responses by interfering with IL-15 signaling pathways. Its primary applications include investigations into immune system regulation, potential therapeutic avenues in autoimmune diseases, and cancer immunotherapy. This reagent is valuable for research focused on cytokine interactions and immune cell activation. -
IL-2 Antibody Inhibitor
Balekafusp alfa is an IgG1K human antibody specifically targeting interleukin-2 (IL-2). It exhibits anti-tumor activity, making it a valuable tool for cancer research and therapeutic studies. This reagent can aid in investigating the immunological mechanisms of IL-2 and its role in tumor progression. Additionally, researchers can utilize it to explore potential applications in immunotherapy and the modulation of immune responses. -
IL-17 Inhibitor
IL-17-IN-5 is a potent inhibitor of interleukin-17 (IL-17) with an IC50 of less than 0.1 μM. This compound is designed for research applications related to inflammatory diseases, facilitating the study of IL-17's role in various pathophysiological processes. IL-17-IN-5 can aid in the development of therapeutic strategies targeting IL-17 signaling pathways. -
IL-1 Inhibitor
Triptoquinone B is a sesquiterpene alkaloid that functions as an interleukin-1 inhibitor. It exhibits significant inhibitory effects on the release of interleukin 1α and 1β from human peripheral mononuclear cells, making it a valuable reagent for studies focused on inflammatory processes and cytokine signaling. This compound is useful for research into immune responses and related therapeutic applications. - Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.
-
IL-12/IL-23 inhibitor
Apilimod (STA 5326) mesylate is a potent IL-12/IL-23 inhibitor, and strongly inhibits IL-12 with IC50s of 1 nM and 2 nM, in IFN-γ/SAC-stimulated human PBMCs and SAC-treated monkey PBMCs, respectively. -
Rab27a-JFC1 Inhibitor
Nexinhib20 is a selective inhibitor of the Rab27a-JFC1 interaction (IC50: 2.6 μM) and Rac-1-GTP signaling. This compound effectively inhibits neutrophil exocytosis, adhesion, and β2 integrin activation, demonstrating significant anti-inflammatory properties. Nexinhib20 is suitable for research applications focused on systemic inflammation and myocardial ischemia-reperfusion injury. -
Endogenous Metabolite
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice. -
PDE Inhibitor
Theophylline, a potent phosphodiesterase (PDE) inhibitor, primarily targets PDE3, leading to relaxation of airway smooth muscle and enhanced bronchodilation. This compound also functions as an adenosine receptor antagonist and exhibits anti-inflammatory properties by elevating IL-10 levels and inhibiting NF-κB translocation into the nucleus. Additionally, Theophylline has been shown to induce apoptosis in certain cell types. Its applications are particularly relevant in the research of asthma and chronic obstructive pulmonary disease (COPD). -
AMPK Agonist
10-Gingerol is an AMPK agonist derived from ginger oleoresin, exhibiting notable anti-inflammatory, antioxidant, and anti-proliferative properties. It effectively suppresses neointimal hyperplasia and inhibits the proliferation of vascular smooth muscle cells. Demonstrating significant radical scavenging activities, 10-Gingerol has IC50 values of 10.47 μM against DPPH, 1.68 μM against superoxide, and 1.35 μM against hydroxyl radicals. This compound also inhibits MDA-MB-231 tumor cell line proliferation with an IC50 of 12.1 μM, while targeting the PI3K/Akt signaling pathway to suppress proliferation, migration, invasion, and promote apoptosis. It holds potential for research applications in ulcerative colitis. -
TNF Receptor Inhibitor
Muscone, a TNF receptor inhibitor, is derived from the traditional Chinese medicine musk. It effectively inhibits NF-κB signaling and NLRP3 inflammasome activation, resulting in a significant reduction of inflammatory cytokines such as IL-1β, TNF-α, and IL-6. This compound is valuable in research focused on inflammation, cardiac function restoration, and improving survival rates in various pathological conditions. -
Anti-Inflammatory/Antibacterial Agent
(20R)-Protopanaxadiol acts as an anti-inflammatory and antibacterial agent, derived from ginsenosides. It effectively exhibits anti-inflammatory properties while maintaining a lack of significant cytotoxicity against tumor cell lines. Additionally, (20R)-Protopanaxadiol has been shown to inhibit the uptake of 2-deoxy-D-glucose (2-DG), making it relevant for research applications focusing on metabolic pathways and the modulation of inflammatory processes.
